PROM1 and colorectal cancer: Recently, a clinical trial testing CD133-directed CAR T-cells in patients with ALL, AML, breast, brain, liver, pancreatic and ovarian cancers as well as colorectal cancers has been completed (NCT02541370, Table 9).